Emerging Role of Circulating Tumor DNA in the Management of Thoracic Malignancies (Sept. 26, 2024)

Circulating tumor DNA (ctDNA) is a blood test that can be used to detect and monitor thoracic malignancies. It is being used to detect mutations, monitor for recurrence after surgery and other treatments, and can even be used in conjunction with screening to help identify malignancy. As the field continues to advance, it is crucial for thoracic surgeons, trainees, and healthcare providers to stay informed about the latest developments in ctDNA testing and its applications for thoracic patients. Sponsored by AstraZeneca